8-K current report · filed Nov 3, 2026

Guardant Health, Inc. (GH) 8-K Current Report: November 3, 2026

Item 5.02Item EX-99.1GH overview

Short answer

Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 11 directors with Kevin R. Sayer appointed Class II director through 2029 annual meeting.

Guardant Health, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded to 11 directors with Kevin R. Sayer appointed Class II director through 2029 annual meeting
  • Sayer brings Dexcom leadership experience, including CEO through January 2026 and executive chairman effective January 2026
  • Director compensation: $500,000 restricted stock unit award vesting over three years, plus $60,000 annual cash retainer
  • Robert A. Parks appointed Chief Accounting Officer and principal accounting officer, strengthening accounting leadership after roles at Fortrea, NetApp and IQVIA
  • Parks eligible for annual salary, incentive bonus and restricted stock unit awards under the 2023 inducement plan

Item EX-99.1 · Exhibit EX-99.1

  • Kevin Sayer appointed to Guardant Health’s board, adding former Dexcom CEO and current Executive Chairman
  • Sayer brings digital health, medical technology, and operational scaling experience from Dexcom and prior healthcare roles
  • Appointment supports Guardant’s strategy in liquid biopsy, AI-enabled molecular data, early cancer detection, and personalized treatment
  • Board addition may strengthen healthcare-industry credibility and strategic execution as Guardant expands precision oncology offerings

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Guardant Health, Inc. 8-K filings

Get the next GH 8-K as it lands

Follow GH for push alerts, or ask the research agent what this filing means.